Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mohan Somasundaran is active.

Publication


Featured researches published by Mohan Somasundaran.


Nature | 2003

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Wenhui Li; Michael J. Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A. Berne; Mohan Somasundaran; John L. Sullivan; Katherine Luzuriaga; Thomas C. Greenough; Hyeryun Choe; Michael Farzan

Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute respiratory syndrome (SARS), associate with cellular receptors to mediate infection of their target cells. Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), isolated from SARS coronavirus (SARS-CoV)-permissive Vero E6 cells, that efficiently binds the S1 domain of the SARS-CoV S protein. We found that a soluble form of ACE2, but not of the related enzyme ACE1, blocked association of the S1 domain with Vero E6 cells. 293T cells transfected with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinucleated syncytia with cells expressing S protein. Furthermore, SARS-CoV replicated efficiently on ACE2-transfected but not mock-transfected 293T cells. Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells. Together our data indicate that ACE2 is a functional receptor for SARS-CoV.


The Journal of Infectious Diseases | 1997

Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes (CTL), Virus Load, and CD4 T Cell Loss: Evidence Supporting a Protective Role for CTL In Vivo

Thomas C. Greenough; Doreen B. Brettler; Mohan Somasundaran; Dennis Panicali; John L. Sullivan

The relationships between primary human immunodeficiency virus type 1 (HIV-1) Gag-specific cytotoxic T lymphocyte (CTL) frequency, virus load, and CD4 T cell loss were evaluated in a group of 46 HIV-1-infected persons with hemophilia. Freshly isolated peripheral blood mononuclear cells in limiting dilution assays were used to measure HIV-1 Gag-specific CTL frequencies. Concurrent measurements of virus load and lymphocyte surface markers were obtained. No correlation between Gag-specific CTL frequency and concurrent CD4 cell count was observed. A significant inverse relationship was observed between HIV-1 Gag-specific CTL frequency and provirus load as measured by polymerase chain reaction. Subjects with higher CTL frequencies were found to have more stable CD4 cell counts over time. These results provide additional evidence to support the concept that the predominant role of this virus-specific cellular immune response is to limit viral replication and CD4 cell loss in HIV-1 infection.


The New England Journal of Medicine | 2015

Viremic relapse after HIV-1 remission in a perinatally infected child

Katherine Luzuriaga; Carrie Ziemniak; Keri B. Sanborn; Mohan Somasundaran; Kaitlin Rainwater-Lovett; John W. Mellors; Daniel I. S. Rosenbloom; Deborah Persaud

Recently the “Mississippi Child” was reported as having a prolonged clearance of HIV viremia after the initiation of antiretroviral therapy shortly after birth. Further follow-up of this case is now reported.


Structure | 2010

Crystal Structure of the APOBEC3G Catalytic Domain Reveals Potential Oligomerization Interfaces

Shivender M.D. Shandilya; Madhavi N. L. Nalam; Ellen A. Nalivaika; Phillip J. Gross; Johnathan C. Valesano; Keisuke Shindo; Ming Li; Mary Munson; William E. Royer; Takahide Kono; Hiroshi Matsuo; Reuben S. Harris; Mohan Somasundaran; Celia A. Schiffer

APOBEC3G is a DNA cytidine deaminase that has antiviral activity against HIV-1 and other pathogenic viruses. In this study the crystal structure of the catalytically active C-terminal domain was determined to 2.25 A. This structure corroborates features previously observed in nuclear magnetic resonance (NMR) studies, a bulge in the second beta strand and a lengthening of the second alpha helix. Oligomerization is postulated to be critical for the function of APOBEC3G. In this structure, four extensive intermolecular interfaces are observed, suggesting potential models for APOBEC3G oligomerization. The structural and functional significance of these interfaces was probed by solution NMR and disruptive variants were designed and tested for DNA deaminase and anti-HIV activities. The variant designed to disrupt the most extensive interface lost both activities. NMR solution data provides evidence that another interface, which coordinates a novel zinc site, also exists. Thus, the observed crystallographic interfaces of APOBEC3G may be important for both oligomerization and function.


The Journal of Infectious Diseases | 2005

Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice

Thomas C. Greenough; Gregory J. Babcock; Anjeanette Roberts; Hector J. Hernandez; William D. Thomas; Jennifer A. Coccia; Robert F. Graziano; Mohan Srinivasan; Israel Lowy; Robert W. Finberg; Kanta Subbarao; Leatrice Vogel; Mohan Somasundaran; Katherine Luzuriaga; John L. Sullivan; Donna M. Ambrosino

Abstract Background. Severe acute respiratory syndrome (SARS) remains a significant public health concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARSCoV) could provide protection for exposed individuals. Methods. Transgenic mice with human immunoglobulin genes were immunized with the recombinant major surface (S) glycoprotein ectodomain of SARS-CoV. Epitopes of 2 neutralizing MAbs derived from these mice were mapped and evaluated in a murine model of SARS-CoV infection. Results. Both MAbs bound to S glycoprotein expressed on transfected cells but differed in their ability to block binding of S glycoprotein to Vero E6 cells. Immunoprecipitation analysis revealed 2 antibody-binding epitopes: one MAb (201) bound within the receptor-binding domain at aa 490–510, and the other MAb (68) bound externally to the domain at aa 130–150. Mice that received 40 mg/kg of either MAb prior to challenge with SARS-CoV were completely protected from virus replication in the lungs, and doses as low as 1.6 mg/kg offered significant protection. Conclusions. Two neutralizing epitopes were defined for MAbs to SARS-CoV S glycoprotein. Antibodies to both epitopes protected mice against SARS-CoV challenge. Clinical trials are planned to test MAb 201, a fully human MAb specific for the epitope within the receptor-binding region.


Proceedings of the National Academy of Sciences of the United States of America | 2002

Evidence for a cytopathogenicity determinant in HIV-1 Vpr

Mohan Somasundaran; Mark Sharkey; Beda Brichacek; Katherine Luzuriaga; Michael Emerman; John L. Sullivan; Mario Stevenson

HIV-1 is cytopathic for CD4+ T lymphocytes in vitro and this property of HIV-1 is generally considered to account for some of its in vivo cytopathogenicity. Thus, the extent of lymphocyte depletion correlates with the level of viremia whereas low levels of viral replication are typically associated with stable lymphocyte levels and asymptomatic infection such as is observed in non-progressors. Here, we describe a non-progressor who did not fit this general pattern in that CD4+ T lymphocyte homeostasis was maintained in the face of high-level viral replication. Biological viral isolates from this patient replicated in primary lymphocytes without inducing cytopathicity. Because this phenotype is reminiscent of Vpr-deleted viruses, we examined the contribution of the Vpr gene to the viral phenotype. Vpr alleles derived from this patient contained both premature stop codons and an unusual Q3R polymorphism. Insertion of patient-derived Vpr alleles or a Q3R substitution into a cytopathic HIV-1 clone resulted in a marked impairment of cytopathicity without affecting viral replication efficiency. The effect of Vpr on cytopathicity was unrelated to reported activities of Vpr including virion association, interaction with uracil DNA glycosylase, G2 arrest, or enhancement of macrophage infection but correlated with the ability of Vpr to induce host cell apoptosis. This study suggests the presence of a determinant of in vivo cytopathogenicity within HIV-1 Vpr and further indicates that viral replication can be uncoupled from cytopathicity in vitro and in vivo.


Journal of Immunology | 2003

Differential Kinetics and Specificity of EBV-Specific CD4+ and CD8+ T Cells During Primary Infection

Melissa L. Precopio; John L. Sullivan; Courtney Willard; Mohan Somasundaran; Katherine Luzuriaga

The generation and maintenance of virus-specific CD4+ T cells in humans are not well understood. We used short in vitro stimulation assays followed by intracellular cytokine staining to characterize the timing, magnitude, and Ag specificity of CD4+ T cells over the course of primary EBV infection. Lytic and latent protein-specific CD4+ T cells were readily detected at presentation with acute infectious mononucleosis and declined rapidly thereafter. Responses to BZLF-1, BMLF-1, and Epstein-Barr nuclear Ag-3A were more commonly detected than responses to Epstein-Barr nuclear Ag-1. Concurrent analyses of BZLF-1-specific CD4+ and CD8+ T cells revealed differences in the expansion, specificity, and stability of CD4+ and CD8+ T cell-mediated responses over time. Peripheral blood EBV load directly correlated with the frequency of EBV-specific CD4+ T cell responses at presentation and over time, suggesting that EBV-specific CD4+ T cell responses are Ag-driven.


Structure | 2013

Crystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding Domain

Markus Frederik Bohn; Shivender M.D. Shandilya; John S. Albin; Takahide Kouno; Brett D. Anderson; Rebecca M. McDougle; Michael A. Carpenter; Anurag Rathore; Leah Evans; Ahkillah N. Davis; JingYing Zhang; Yongjian Lu; Mohan Somasundaran; Hiroshi Matsuo; Reuben S. Harris; Celia A. Schiffer

Human APOBEC3F is an antiretroviral single-strand DNA cytosine deaminase, susceptible to degradation by the HIV-1 protein Vif. In this study the crystal structure of the HIV Vif binding, catalytically active, C-terminal domain of APOBEC3F (A3F-CTD) was determined. The A3F-CTD shares structural motifs with portions of APOBEC3G-CTD, APOBEC3C, and APOBEC2. Residues identified to be critical for Vif-dependent degradation of APOBEC3F all fit within a predominantly negatively charged contiguous region on the surface of A3F-CTD. Specific sequence motifs, previously shown to play a role in Vif susceptibility and virion encapsidation, are conserved across APOBEC3s and between APOBEC3s and HIV-1 Vif. In this structure these motifs pack against each other at intermolecular interfaces, providing potential insights both into APOBEC3 oligomerization and Vif interactions.


ACS Chemical Biology | 2012

First-In-Class Small Molecule Inhibitors of the Single-Strand DNA Cytosine Deaminase APOBEC3G

Ming Li; Shivender M.D. Shandilya; Michael A. Carpenter; Anurag Rathore; William L. Brown; Angela L. Perkins; Daniel A. Harki; Jonathan Solberg; Derek J. Hook; Krishan K. Pandey; Michael A. Parniak; Jeffrey R. Johnson; Nevan J. Krogan; Mohan Somasundaran; Akbar Ali; Celia A. Schiffer; Reuben S. Harris

APOBEC3G is a single-stranded DNA cytosine deaminase that comprises part of the innate immune response to viruses and transposons. Although APOBEC3G is the prototype for understanding the larger mammalian polynucleotide deaminase family, no specific chemical inhibitors exist to modulate its activity. High-throughput screening identified 34 compounds that inhibit APOBEC3G catalytic activity. Twenty of 34 small molecules contained catechol moieties, which are known to be sulfhydryl reactive following oxidation to the orthoquinone. Located proximal to the active site, C321 was identified as the binding site for the inhibitors by a combination of mutational screening, structural analysis, and mass spectrometry. Bulkier substitutions C321-to-L, F, Y, or W mimicked chemical inhibition. A strong specificity for APOBEC3G was evident, as most compounds failed to inhibit the related APOBEC3A enzyme or the unrelated enzymes E. coli uracil DNA glycosylase, HIV-1 RNase H, or HIV-1 integrase. Partial, but not complete, sensitivity could be conferred to APOBEC3A by introducing the entire C321 loop from APOBEC3G. Thus, a structural model is presented in which the mechanism of inhibition is both specific and competitive, by binding a pocket adjacent to the APOBEC3G active site, reacting with C321, and blocking access to substrate DNA cytosines.


Journal of Virology | 2004

Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2.

Wenhui Li; Thomas C. Greenough; Michael J. Moore; Natalya Vasilieva; Mohan Somasundaran; John L. Sullivan; Michael Farzan; Hyeryun Choe

ABSTRACT Replication of viruses in species other than their natural hosts is frequently limited by entry and postentry barriers. The coronavirus that causes severe acute respiratory syndrome (SARS-CoV) utilizes the receptor angiotensin-converting enzyme 2 (ACE2) to infect cells. Here we compare human, mouse, and rat ACE2 molecules for their ability to serve as receptors for SARS-CoV. We found that, compared to human ACE2, murine ACE2 less efficiently bound the S1 domain of SARS-CoV and supported less-efficient S protein-mediated infection. Rat ACE2 was even less efficient, at near background levels for both activities. Murine 3T3 cells expressing human ACE2 supported SARS-CoV replication, whereas replication was less than 10% as efficient in the same cells expressing murine ACE2. These data imply that a mouse transgenically expressing human ACE2 may be a useful animal model of SARS.

Collaboration


Dive into the Mohan Somasundaran's collaboration.

Top Co-Authors

Avatar

Katherine Luzuriaga

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

John L. Sullivan

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Thomas C. Greenough

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Celia A. Schiffer

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Shivender M.D. Shandilya

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Doreen B. Brettler

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Eric R. Weiss

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Frank E. Brewster

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Brian A. Kelch

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Ellen A. Nalivaika

University of Massachusetts Medical School

View shared research outputs
Researchain Logo
Decentralizing Knowledge